World’s First COVID-19 Vaccine Launched by Russia Ahead of Completion of Final Testing
|
By HospiMedica International staff writers Posted on 12 Aug 2020 |

Illustration
Russia became the first country to approve an experimental COVID-19 vaccine which will be administered to millions of people, including thousands of teachers and front-line health-care workers over the coming weeks even before the completion of its clinical trial.
Announcing the Health Ministry’s approval, Russian President Vladimir Putin said that the vaccine, named Sputnik-V, had undergone the necessary tests and had demonstrated providing lasting immunity to the coronavirus, according to the Associated Press. However, Russian authorities are yet to offer any proof to back up claims of safety or effectiveness of the COVID-19 vaccine.
Sputnik-V has been tested on some volunteers, although Russia has not yet completed the larger type of study required to prove its safety and protection against infection by the coronavirus. Russian scientists have not yet published any scientific information about the vaccine’s performance in animal tests or early-stage human studies. As a result, scientists in Russia and across the world have expressed concern that offering the vaccine before the completion of final-stage testing could be dangerous.
Similar to the approach adopted for the AstraZeneca-Oxford COVID-19 vaccine, the Sputnik-V vaccine also uses the common cold-causing adenovirus that has been modified to carry genes for the “spike” protein that coats the coronavirus, in order to prime the body to recognize if a real COVID-19 infection strikes. The vaccine, developed jointly by the Gamaleya Research Institute and the Russian Defense Ministry, has two separately-injected components that together are expected to build a long-term immunity against the virus. A recent statement by the Russian Health Ministry said that the vaccine is expected to provide immunity from the coronavirus for up to two years, based on its experience with vaccines developed using similar technology. Russia has reportedly received preliminary applications for over one billion doses of the Sputnik-V vaccine from 20 countries and was ready to manufacture 500 million doses of the vaccine annually in five countries. Amidst warnings by experts that improperly tested vaccines could be harmful to health and undermine trust in vaccinations, Russia plans to start vaccinating doctors as early as this month and mass vaccinations by October.
“Fast-tracked approval will not make Russia the leader in the race, it will just expose consumers of the vaccine to unnecessary danger,” said Russia’s Association of Clinical Trials Organizations, in urging government officials to postpone approving the vaccine without completed advanced trials.
Announcing the Health Ministry’s approval, Russian President Vladimir Putin said that the vaccine, named Sputnik-V, had undergone the necessary tests and had demonstrated providing lasting immunity to the coronavirus, according to the Associated Press. However, Russian authorities are yet to offer any proof to back up claims of safety or effectiveness of the COVID-19 vaccine.
Sputnik-V has been tested on some volunteers, although Russia has not yet completed the larger type of study required to prove its safety and protection against infection by the coronavirus. Russian scientists have not yet published any scientific information about the vaccine’s performance in animal tests or early-stage human studies. As a result, scientists in Russia and across the world have expressed concern that offering the vaccine before the completion of final-stage testing could be dangerous.
Similar to the approach adopted for the AstraZeneca-Oxford COVID-19 vaccine, the Sputnik-V vaccine also uses the common cold-causing adenovirus that has been modified to carry genes for the “spike” protein that coats the coronavirus, in order to prime the body to recognize if a real COVID-19 infection strikes. The vaccine, developed jointly by the Gamaleya Research Institute and the Russian Defense Ministry, has two separately-injected components that together are expected to build a long-term immunity against the virus. A recent statement by the Russian Health Ministry said that the vaccine is expected to provide immunity from the coronavirus for up to two years, based on its experience with vaccines developed using similar technology. Russia has reportedly received preliminary applications for over one billion doses of the Sputnik-V vaccine from 20 countries and was ready to manufacture 500 million doses of the vaccine annually in five countries. Amidst warnings by experts that improperly tested vaccines could be harmful to health and undermine trust in vaccinations, Russia plans to start vaccinating doctors as early as this month and mass vaccinations by October.
“Fast-tracked approval will not make Russia the leader in the race, it will just expose consumers of the vaccine to unnecessary danger,” said Russia’s Association of Clinical Trials Organizations, in urging government officials to postpone approving the vaccine without completed advanced trials.
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans
Channels
Artificial Intelligence
view channelAI Analysis of Pericardial Fat Refines Long-Term Heart Disease Risk
Accurately identifying long-term cardiovascular disease risk in asymptomatic adults remains challenging for clinicians. Missed or underestimated risk delays preventive therapy and increases the chance... Read more
Machine Learning Approach Enhances Liver Cancer Risk Stratification
Hepatocellular carcinoma, the most common form of primary liver cancer, is often detected late despite targeted surveillance programs. Current screening guidelines emphasize patients with known cirrhosis,... Read moreCritical Care
view channel
Eye Imaging AI Identifies Elevated Cardiovascular Risk
Many adults at risk for atherosclerotic cardiovascular disease are not identified until they undergo formal primary care assessment. Delayed risk recognition can postpone initiation of statins and lifestyle... Read more
Noninvasive Monitoring Device Enables Earlier Intervention in Heart Failure
Hospitalizations for heart failure with preserved ejection fraction (HFpEF) remain common because lung congestion often worsens before symptoms prompt treatment changes. Missed early decompensation... Read moreSurgical Techniques
view channel
Fiber-Form Bone Graft Expands Intraoperative Options for Spinal Fusion
Spinal and orthopedic fusion procedures often require bone graft materials that handle predictably and support bone formation. Surgeons face added complexity in difficult anatomy and challenging fusion environments.... Read more
Ultrasound‑Aided Catheter Treatment Cuts Early Collapse in Pulmonary Embolism
Acute pulmonary embolism can cause rapid hemodynamic deterioration and early death in hospitalized and emergency patients. Systemic thrombolysis can dissolve clots but is limited by a high risk of major... Read morePatient Care
view channel
Wearable Sleep Data Predict Adherence to Pulmonary Rehabilitation
Chronic obstructive pulmonary disease (COPD) is a long-term lung disorder that makes breathing difficult and often disturbs sleep, reducing energy for daily activities. Limited engagement in pulmonary... Read more
Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read moreHealth IT
view channel
Voice-Driven AI System Enables Structured GI Procedure Documentation
Documentation during gastrointestinal (GI) procedures often competes with real-time clinical decision-making and imposes a significant cognitive burden on physicians. Manual data entry and post-procedure... Read more
EMR-Based Tool Predicts Graft Failure After Kidney Transplant
Kidney transplantation offers patients with end-stage kidney disease longer survival and better quality of life than dialysis, yet graft failure remains a major challenge. Although a successful transplant... Read more
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read moreBusiness
view channel








